Director received an award of 272 CYTK shares | OQRO Insider tradesWhy it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Jul 15, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Jul 16, 2026
DirectorGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001061983-26-000080
- Filed / recorded
Added to OQROOct 6, 2026, 7:14 PM UTC Data qualityVerified: identifiers matched exactly Reporting personJohn T Henderson TableNon-derivative (Table I) Transaction dateJul 15, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.
Around the same time
Derivative exercise or conversion — not an open-market buy.
CEO sold ~$576K of Cytokinetics
Automatic saleDerivative exercise or conversion — not an open-market buy.